TNFRSF8 and anaplastic large cell lymphoma: While 15 of the 17 patients enrolled had Hodgkin lymphoma, the two patients with CD30+ ALCL both achieved CRs following single-agent intravenous BV treatment at 1.8 mg/kg every 3 weeks [20].